ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk Schipper of the Dutch Cancer Institute (NKI) have presented their findings on whole genome sequencing.
In the poster presentation
Whole Genome Sequencing (WGS) is feasible in routine clinical care
Kris Samsom of the Dutch Cancer Institute explains the results of their research in which they conclude that WGS is feasible in routine diagnostics.
In the poster presentation
Whole Genome Sequencing (WGS) improves sarcoma diagnosis and patient care
Luuk Schipper of the Dutch Cancer Institute explains how they came to the conclusion in their research that WGS can help improve the diagnosis and the treatment of patients with sarcomas.
More information
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Interview with Kim Monkhorst, patholoog NKI/AvL about the interim results of WIDE: Whole Genome Sequencing feasible in clinical practice
- More information about WGS and the extensive DNA test: OncoAct.nl
All news
Also read
New research shows a more significant role of genetic predisposition in adults with glioblastoma
A recent study published in npj Genomic Medicine shows that hereditary predisposition in adult glioblastoma patients is more common than …
Single WGS analysis of metastases is sufficient in most cases
DNA analysis of the tumor is of crucial importance to determine treatment options for patients with metastasized lung cancer. But …
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
We want to extract the maximum amount of information from the patient’s tumor. This DNA test is the The complete DNA test is the best available tool to extract the maximum amount of information from the patient’s tumor. We only need one tissue sample with sufficient tumor cells. We literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance. This test is tumor-independent and future-proof. These are the two most important advantages of WGS.